Lorenza Mittempergher

Author

Agendia (Netherlands)ORCID

Also Known As

L Mittempergher, L. Mittempergher, Lorenza Mittempergher

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Agendia (Netherlands)The Netherlands Cancer Institute Oncode Institute University of California, San Francisco University of Padua

About

Lorenza Mittempergher is an author at Agendia (Netherlands) specializing in medicine, molecular diagnostics, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	249
2	Engineering	3	3	170
3	Biostatistics	2	2	43
4	Natural Sciences	1	1	24
5	Allergy	1	1	12

Lorenza Mittempergher

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling Sidong Huang, Michael Hölzel, Theo Knijnenburg, Cell	2012	427
<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer Ian J. Majewski, Paolo Nucíforo, Lorenza Mittempergher, Journal of Clinical Oncology	2015	217
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer Magali Michaut, Suet‐Feung Chin, Ian J. Majewski, Scientific Reports	2016	173
Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue Are Largely Comparable to Fresh Frozen Matched Tissue Lorenza Mittempergher, Jorma J. de Ronde, Marja Nieuwland, PLoS ONE	2011	151
Identification of recurrent <i><scp>FGFR3</scp></i> fusion genes in lung cancer through kinome‐centred <scp>RNA</scp> sequencing Ian J. Majewski, Lorenza Mittempergher, N. Davidson, The Journal of Pathology Capture Enrichment StrategyFunctional GenomicsEngineeringTumor HeterogeneityMedicine	2013	117
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, <i>BRCA1</i>-like status, tumor-infiltrating immune cells and survival Marcelo Sobral‐Leite, Koen Van de Vijver, Magali Michaut, OncoImmunology	2018	117
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma Joseph J. Caumanns, Katrien Berns, G. Bea A. Wisman, Clinical Cancer Research	2018	50
FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer Willemijn S.M.E. Theelen, Lorenza Mittempergher, Stefan M. Willems, The Journal of Pathology Clinical Research	2016	46
A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences Lorenza Mittempergher, Mahasti Saghatchian, Denise M. Wolf, Molecular Oncology	2013	43
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test Lorenza Mittempergher, Leonie Delahaye, Anke Witteveen, Translational Oncology	2020	40

Page 1